Longeveron to Participate in Phacilitate Advanced Therapies Week
26 January 2022 - 12:00AM
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a
clinical stage biotechnology company developing cellular therapies
for chronic, aging-related and life-threatening conditions,
announced today that management will be speaking and participating
in several panel and presentation sessions during Phacilitate’s
Advanced Therapies Week from January 25-28, 2022 in Miami Beach,
FL.
Specifically, Longeveron management will
participate in the following sessions at the event:
- Format: Panel Discussion: “Development in
Neurology and Ophthalmology” chaired by Dan Gincel, Ph.D., Senior
Vice President of Strategic Collaborations & Scientific
AffairsDate: Wednesday, January 26,
2022Time: 3:30-5:00pm ET
- Format: Speaker
Presentation: “Phase 2a Clinical Trial of Lomecel-B for the
Treatment of Alzheimer’s Disease” presented by Anthony Oliva, Ph.D.
Senior Scientist Date: Wednesday, January 26,
2022Time: 3:35pm ET
- Format: Panel
Discussion: “Delivery Solutions, Improvements and Alternatives for
Gene & Cell Therapy” chaired by Kevin Ramdas, M.D., M.P.H.,
ACRP-CP., Director of Medical Affairs Date:
Thursday, January 27, 2022Time: 1:30pm – 3:00pm
ET
- Format: Speaker
Presentation: “Technology Transfer from Pre-Clinical to cGMP
Manufacturing – Take the Time to Develop A Solid Suitable Process
From the Start” presented by Lisa McClain-Moss, Vice President of
Manufacturing Date: Thursday, January 27,
2022Time: 1:35pm ET
For more information on the Phacilitate Advanced
Therapies Week and to register for the event, please visit
https://advancedtherapiesweek.phacilitate.com/register-your-place/
.
About Longeveron Inc.Longeveron
is a clinical stage biotechnology company developing cellular
therapies for specific aging-related and life-threatening
conditions. The Company’s lead investigational product is the
LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is
derived from culture-expanded medicinal signaling cells (MSCs) that
are sourced from bone marrow of young, healthy adult donors.
Longeveron believes that by using the same cells that promote
tissue repair, organ maintenance, and immune system function, it
can develop safe and effective therapies for some of the most
difficult disorders associated with the aging process and other
medical disorders. Longeveron is currently sponsoring Phase 1 and 2
clinical trials in the following indications: Aging Frailty,
Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory
Distress Syndrome (ARDS), and hypoplastic left heart syndrome
(HLHS). The Company’s mission is to advance Lomecel-B and other
cell-based product candidates into pivotal Phase 3 trials, with the
goal of achieving regulatory approvals, subsequent
commercialization, and broad use by the healthcare community.
Additional information about the Company is available at
www.longeveron.com.
Contact:Brendan PayneStern
Investor RelationsTel: (212) 362-1200Email:
Brendan.payne@sternir.com
Source: Longeveron
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Jul 2023 to Jul 2024